NEWS BRIEFING: CSIRO starts testing COVID-19 vaccines

Embargoed until: Publicly released:
Not peer-reviewed: This work has not been scrutinised by independent experts, or the story does not contain research data to review (for example an opinion piece). If you are reporting on research that has yet to go through peer-review (eg. conference abstracts and preprints) be aware that the findings can change during the peer review process.

Experimental study: At least one thing in the experiment was changed to see if it had an impact on the subjects (often people or animals) – eg: changing the amount of time mice spend on an exercise wheel to find out what impact it has on weight loss.

Animals: This is a study based on research on whole animals.

CSIRO, Australia’s national science agency, has commenced the first stage of testing potential vaccines for COVID-19  at its high-containment facility in Geelong. Join the briefing to hear from the CSIRO about this research milestone, which is an integral part of the rapid global response to the COVID-19 outbreak and how it is helping to fast-track the development of a vaccine.

Organisation/s: CSIRO

Funder: CSIRO

Media release


: Thursday 2 April
Start Time: 09:00am AEDT
Duration: Approx 45 min 
Venue: Online


  • Dr Rob Grenfell, Director Health and Biosecurity, CSIRO
  • Professor Trevor Drew, Director, Australian Animal Health Laboratory, CSIRO

This webcast briefing will include the speakers on video which TV/broadcast may wish to use as interview footage. A recording of the event will also be made available. 

Join the online briefing here:

NOTE: Once logged in please unmute the presentation on the right-hand side of the screen. There is no phone access to this briefing


CSIRO, Australia’s national science agency, has commenced the first stage of testing potential vaccines for COVID-19.  The testing, expected to take three months, is underway at CSIRO’s high-containment biosecurity facility, the Australian Animal Health Laboratory (AAHL) in Geelong.

To prepare for disease outbreaks, last year CSIRO partnered with the Coalition for Epidemic Preparedness Innovations (CEPI), a global group that aims to derail epidemics by speeding up the development of vaccines.

In January, CEPI engaged CSIRO to start working on the virus SARS CoV-2, which causes the disease COVID-19.  In consultation with the World Health Organisation, CEPI has identified vaccine candidates from The University of Oxford (UK) and Inovio Pharmaceuticals Inc. (US) to undergo the first pre-clinical trials at CSIRO, with further candidates likely to follow.

The latest milestone builds on CSIRO’s growing work to tackle COVID-19, which has included scaling up other potential vaccine candidates at its biologics production facility in Melbourne.

CSIRO Chief Executive, Dr Larry Marshall said, “Beginning vaccine candidate testing at CSIRO is a critical milestone in the fight against COVID-19, made possible by collaboration both within Australia and across the globe.”

“CSIRO researchers are working around-the-clock to combat this disease which is affecting so many – whether it’s at the Australian Animal Health Laboratory (AAHL) or at our state-of-the-art biologics manufacturing facility – we will keep working until this viral enemy is defeated,” Dr Marshall said.

CSIRO is testing the COVID-19 vaccine candidates for effectiveness, but also evaluating the best way to give the vaccine for better protection, including an intra-muscular injection and innovative approaches like a nasal spray.

Professor Trevor Drew OBE, is Director of AAHL and leading CSIRO’s COVID-19 virus and vaccine work.

“We have been studying SARS CoV-2 since January and getting ready to test the first vaccine candidates as soon as they are available.  We are carefully balancing operating at speed with the critical need for safety in response to this global public health emergency.” Professor Drew said.

CSIRO has a long history of developing and testing vaccines since the opening of the AAHL in 1985. It is the only high biocontainment facility in the southern hemisphere working with highly dangerous and exotic pathogens, including diseases that transfer from animals to people.

“Tackling disease and supporting better health outcomes takes a one-health approach,” Dr Marshall said.

“In 2016 CSIRO created the Health and Biosecurity research group who work with our scientists at AAHL to tackle our national and international health and biosecurity challenges together, so we can better protect the health of our people, environment, agriculture and industries and our way of life.

“This, combined with our data science and manufacturing capability in our biological production facility, means we were well prepared to help Australia in One Health with disease identification, prevention and management, to deliver the real world solutions that our nation expects from science,” Dr Marshall said.

CSIRO’s COVID-19 research so far

Current rapid work on COVID-19 spans virus and vaccine:

·         CSIRO was the first research organisation outside of China to generate sufficient stock of the virus —using the virus strain isolated by the Doherty Institute — to enable pre-clinical studies and research on COVID-19.

·         CSIRO successfully established a biological model in March 2020, the first in the world to confirm ferrets react to SARS-CoV-2 (the virus that causes COVID-19). Researchers have quickly progressed to studying the course of infection in the animals – a crucial step in understanding if a vaccine will work. 

·         CSIRO researchers confirmed, after studying SARS CoV-2’s genomic sequence that the virus is presently changing into a number of distinct ‘clusters’ and are now starting to look at how this may also impact on the development of a vaccine.

For more information on CSIRO’s COVID-19 work, visit:


Images and video available for media use here


    Web page
    Join the online briefing here - NOTE: Once logged in please unmute the presentation on the right-hand side of the screen.
    Web page
    Images and video available for media use here
    Web page
    Briefing recording

News for:


Media contact details for this story are only visible to registered journalists.